Home › Asset managers › Guggenheim › 2024-2025 › Against the board
Two kinds of vote are listed: a board-sponsored proposal Guggenheim voted AGAINST or withheld on, and a shareholder proposal it voted FOR. One row is one proposal at one meeting; “funds” is how many of the manager’s funds or accounts voted that way.
Everything Only shareholder proposals it backed
2,596 proposals.
| Company | Meeting | Proposal | Category | On the ballot from | Guggenheim voted | Funds |
|---|---|---|---|---|---|---|
| Precigen, Inc. | 2024-07-05 | Company Proposal - Election of Directors: Steven Frank | Director Elections | Board | AGAINST | 5 |
| Precigen, Inc. | 2025-06-26 | Company Proposal - Approval, in compliance with Nasdaq Listing Rule 5635(c), of the additional issuance of shares of Series A Preferred Stock and Warrants to Randal J. Kirk as PIK dividends, in order for Mr. Kirk to receive PIK dividends on the Series A Preferred Stock on the same terms as the other investors. | Capital Structure | Board | AGAINST | 5 |
| Precigen, Inc. | 2025-06-26 | Company Proposal - Election of Directors: Cesar Alvarez | Director Elections | Board | AGAINST | 5 |
| Prelude Therapeutics Incorporated | 2025-06-12 | Election of Class II Directors: Victor Sandor, M.D.C.M. | Director Elections | Board | ABSTAIN | 5 |
| Pyxis Oncology, Inc. | 2024-10-23 | Approval of an increase in the number of shares of our common stock available for issuance under our 2021 Equity and Incentive Plan by 5,500,000 shares. | Compensation | Board | AGAINST | 5 |
| Pyxis Oncology, Inc. | 2025-06-18 | The election of Class I directors named in the proxy statement: Darren Cline | Director Elections | Board | ABSTAIN | 5 |
| Pyxis Oncology, Inc. | 2025-06-18 | The election of Class I directors named in the proxy statement: Rachel Humphrey, M.D. | Director Elections | Board | ABSTAIN | 5 |
| Pyxis Oncology, Inc. | 2025-06-18 | The election of Class I directors named in the proxy statement: Santhosh Palani, Ph.D., CFA | Director Elections | Board | ABSTAIN | 5 |
| Q32 Bio, Inc. | 2025-06-13 | To elect David Grayzel, M.D., Isaac Manke, Ph.D. and Diyong Xu as Class I directors to our Board of Directors, each to serve until the 2028 Annual Meeting of stockholders and until his successor has been duly elected and qualified, or until his earlier death, resignation, or removal: David Grayzel, M.D. | Director Elections | Board | ABSTAIN | 5 |
| Rackspace Technology, Inc. | 2025-06-20 | Election of Directors: Mitchell Garber | Director Elections | Board | ABSTAIN | 5 |
| Replimune Group, Inc. | 2024-09-04 | Election of Directors: Dieter Weinand | Director Elections | Board | ABSTAIN | 5 |
| Sleep Number Corporation | 2025-05-28 | Approve Amendment to the Sleep Number Corporation 2020 Equity Incentive Plan to increase the number of shares reserved for issuance by 500,000 shares | Compensation | Board | AGAINST | 5 |
| Smith & Wesson Brands, Inc. | 2024-09-17 | A stockholder proposal (human rights impact assessment); | Human Rights or Human Capital/workforce | Shareholder | FOR | 5 |
| Solid Biosciences Inc. | 2025-06-12 | Election of Class I Directors: Alexander Cumbo | Director Elections | Board | ABSTAIN | 5 |
| Solid Biosciences Inc. | 2025-06-12 | Election of Class I Directors: Sukumar Nagendran | Director Elections | Board | ABSTAIN | 5 |
| Solid Biosciences Inc. | 2025-06-12 | The approval of an amendment to the Company's Amended and Restated 2020 Equity Incentive Plan to increase the number of shares of our common stock available for issuance thereunder by 9,000,000 shares and amend the evergreen provision. | Compensation | Board | AGAINST | 5 |
| Solo Brands, Inc. | 2025-05-23 | Election of Directors: Andrea K. Tarbox | Director Elections | Board | ABSTAIN | 5 |
| Standard BioTools Inc. | 2025-06-18 | To approve an amendment to our Amended and Restated 2011 Equity Incentive Plan, as amended, to increase the number of shares of common stock available for issuance thereunder by 17,400,000 shares. | Compensation | Board | AGAINST | 5 |
| Star Holdings | 2025-05-21 | Election of Trustees: Clifford De Souza | Director Elections | Board | ABSTAIN | 5 |
| Star Holdings | 2025-05-21 | Election of Trustees: Nina Matis | Director Elections | Board | ABSTAIN | 5 |
| Star Holdings | 2025-05-21 | Election of Trustees: Richard Lieb | Director Elections | Board | ABSTAIN | 5 |
| Stem, Inc. | 2025-06-04 | To approve an amendment and restatement of the Stem, Inc. 2024 Equity Incentive Plan to increase the number of shares available for issuance by 7,500,000 shares and to extend the plan term. | Compensation | Board | AGAINST | 5 |
| Stitch Fix, Inc. | 2024-12-12 | Election of Directors: Sharon McCollam | Director Elections | Board | ABSTAIN | 5 |
| Sutro Biopharma, Inc. | 2025-06-06 | Election of Class I Directors: Heidi Hunter | Director Elections | Board | ABSTAIN | 5 |
| Sutro Biopharma, Inc. | 2025-06-06 | Election of Class I Directors: Jon Wigginton, M.D. | Director Elections | Board | ABSTAIN | 5 |
| Sutro Biopharma, Inc. | 2025-06-06 | Election of Class I Directors: Michael Dybbs, Ph.D. | Director Elections | Board | ABSTAIN | 5 |
| Taysha Gene Therapies, Inc. | 2025-06-02 | To elect the Board's Class II Director nominees, Phillip B. Donenberg, CPA and Sukumar Nagendran, MD to the Board of Directors to hold office until the 2028 Annual Meeting of Stockholders: Phillip B. Donenberg, CPA | Director Elections | Board | ABSTAIN | 5 |
| Tenaya Therapeutics, Inc. | 2025-05-28 | To elect three Class I directors to hold office until our 2028 annual meeting of stockholders and until their respective successors are elected and qualified: David Goeddel, Ph.D. | Director Elections | Board | ABSTAIN | 5 |
| The E.W. Scripps Company | 2025-05-05 | Election of Directors: Kim Williams | Director Elections | Board | ABSTAIN | 5 |
| The Trade Desk, Inc. | 2024-11-14 | The approval of the reincorporation of The Trade Desk, Inc. from the State of Delaware to the State of Nevada by conversion. | Extraordinary Transactions | Board | AGAINST | 5 |
| The Trade Desk, Inc. | 2025-05-27 | The approval of The Trade Desk, Inc. 2025 Incentive Award Plan, which is an amendment and restatement of our 2016 Incentive Award Plan. | Compensation | Board | AGAINST | 5 |
| Tilly's, Inc. | 2025-06-11 | Election of the following directors for a term expiring at the 2026 annual meeting of stockholders and until their successors are duly elected and qualified: Hezy Shaked | Director Elections | Board | ABSTAIN | 5 |
| Torrid Holdings Inc. | 2025-06-04 | DIRECTOR NOMINEES TO SERVE FOR A THREE-YEAR TERM EXPIRING AT THE FISCAL YEAR 2028 ANNUAL MEETING: Lisa M. Harper | Director Elections | Board | ABSTAIN | 5 |
| Trip.com Group Limited | 2025-06-30 | Elect Rong Luo as Director | Director Elections | Board | AGAINST | 5 |
| Under Armour, Inc. | 2024-09-04 | Election of Directors: Carolyn N. Everson | Director Elections | Board | ABSTAIN | 5 |
| Under Armour, Inc. | 2024-09-04 | Election of Directors: Eric T. Olson | Director Elections | Board | ABSTAIN | 5 |
| Under Armour, Inc. | 2024-09-04 | Election of Directors: Jerri L. DeVard | Director Elections | Board | ABSTAIN | 5 |
| Under Armour, Inc. | 2024-09-04 | Election of Directors: Karen W. Katz | Director Elections | Board | ABSTAIN | 5 |
| Under Armour, Inc. | 2024-09-04 | Election of Directors: Kevin A. Plank | Director Elections | Board | ABSTAIN | 5 |
| Werewolf Therapeutics, Inc. | 2025-06-12 | Election of three directors to serve as Class I directors, each for a three-year term expiring at the 2028 Annual Meeting of Shareholders: Briggs Morrison, M.D. | Director Elections | Board | ABSTAIN | 5 |
| Zentalis Pharmaceuticals, Inc. | 2025-06-17 | Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Scott Myers | Director Elections | Board | ABSTAIN | 5 |
| iRobot Corporation | 2025-05-16 | Approve an amendment to the iRobot Corporation 2018 Stock Option and Incentive Plan, as amended (the "2018 Plan"), to increase the maximum number of shares reserved for issuance under the 2018 Plan. | Compensation | Board | AGAINST | 5 |
| 1st Source Corporation | 2025-04-24 | Election of Directors for terms expiring April 2028: Daniel B. Fitzpatrick | Director Elections | Board | AGAINST | 4 |
| 1st Source Corporation | 2025-04-24 | Election of Directors for terms expiring April 2028: John F. Affleck-Graves | Director Elections | Board | AGAINST | 4 |
| 23andMe Holding Co. | 2024-08-26 | Elect two Class III Director Nominees: Anne Wojcicki | Director Elections | Board | ABSTAIN | 4 |
| 23andMe Holding Co. | 2024-08-26 | Elect two Class III Director Nominees: Peter Taylor | Director Elections | Board | ABSTAIN | 4 |
| 374Water Inc. | 2025-06-11 | Approval of certain amendments to the Company's 2021 Equity Incentive Plan to (i) increase the amount of authorized common stock of the Company issuable under the 2021 Equity Incentive Plan by 12,150,000 shares and (ii) increase the individual non-employee director compensation limit to $300,000 in any calendar year. | Compensation | Board | AGAINST | 4 |
| 374Water Inc. | 2025-06-11 | Election of Directors: Deanna Rene Estes | Director Elections | Board | ABSTAIN | 4 |
| 374Water Inc. | 2025-06-11 | Election of Directors: James M. Vanderhider | Director Elections | Board | ABSTAIN | 4 |
| 4D Molecular Therapeutics, Inc. | 2025-06-17 | Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Jacob Chacko, M.D., MBA | Director Elections | Board | ABSTAIN | 4 |
| 89bio, Inc. | 2025-05-28 | Election of Directors: To be elected for terms expiring in 2028: Derek DiRocco, Ph.D. | Director Elections | Board | ABSTAIN | 4 |
| 908 Devices Inc. | 2025-06-12 | To elect three Class II directors to hold office until the 2028 annual meeting of stockholders: Kevin J. Knopp, Ph.D. | Director Elections | Board | ABSTAIN | 4 |
| A10 Networks, Inc. | 2025-04-17 | To elect five directors to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified: Tor R. Braham | Director Elections | Board | ABSTAIN | 4 |
| ACV Auctions Inc. | 2025-05-28 | Elect two Class I directors: George Chamoun | Director Elections | Board | ABSTAIN | 4 |
| ACV Auctions Inc. | 2025-05-28 | Elect two Class I directors: Robert P. Goodman | Director Elections | Board | ABSTAIN | 4 |
| ADC Therapeutics SA | 2024-11-11 | Approving amendments to Article 4a of the articles of association to increase the Company's capital range The Board of Directors proposes that the amendments to Article 4a of the articles of association to increase the Company's capital range be approved. | Capital Structure | Board | AGAINST | 4 |
| ADC Therapeutics SA | 2024-11-11 | Approving amendments to Article 4c of the articles of association to Increase the Company's conditional share capital for financing, acquisitions and other purposes The Board of Directors proposes that the amendments to Article 4c of the articles of association to increase the Company's conditional share capital for financing, acquisitions and other purposes be approved. | Capital Structure | Board | AGAINST | 4 |
| ADC Therapeutics SA | 2025-06-03 | Approving amendments to article 4b of the articles of association to increase the Company's conditional share capital for employee participation The Board of Directors is proposing that the amendments to article 4b paragraph 1 of the articles of association to increase the Company's conditional share capital for employee participation from 9,547,482 common shares (CHF 763,798.56) to 12,776,259 common shares (CHF 1,022,100.72) be approved, as follows (amendment underlined for ease of reference): "The share capital may be increased in an amount not to exceed CHF 1,022,100.72 through the issuance of up to 12,776,259 fully paid in registered shares with a par value of CHF 0.08 per share through the direct or indirect issuance of shares, or through the exercise or mandatory exercise of rights to acquire shares or through obligations to acquire shares, which were granted to or imposed on members of the Board of Directors, members of the executive management, employees, contractors or consultants of the Company or its group companies, or other persons providing services to the Company or its group companies." | Capital Structure | Board | AGAINST | 4 |
| ADC Therapeutics SA | 2025-06-03 | Approving an amendment to increase the number of shares authorized under the 2019 Equity Incentive Plan The Board of Directors is proposing that an amendment to increase the number of shares authorized under 2019 Equity Incentive Plan be approved. | Compensation | Board | AGAINST | 4 |
| ADC Therapeutics SA | 2025-06-03 | Approving, on a binding basis under Swiss law, the compensation of the Board of Directors and the Executive Committee The Board of Directors proposes that the maximum aggregate amount of compensation for the members of the Board of Directors for the period between the Annual Meeting and the 2026 annual general meeting of Shareholders be set at $2,300,000. | Compensation | Board | AGAINST | 4 |
| AMC Networks Inc. | 2025-06-05 | Advisory vote on Named Executive Officer compensation | Say-on-Pay | Board | AGAINST | 4 |
| AMC Networks Inc. | 2025-06-05 | Election of the following nominees as Directors: Carl E. Vogel | Director Elections | Board | ABSTAIN | 4 |
| AMC Networks Inc. | 2025-06-05 | Election of the following nominees as Directors: Debra G. Perelman | Director Elections | Board | ABSTAIN | 4 |
| AMC Networks Inc. | 2025-06-05 | Election of the following nominees as Directors: Joseph M. Cohen | Director Elections | Board | ABSTAIN | 4 |
| AMC Networks Inc. | 2025-06-05 | Election of the following nominees as Directors: Leonard Tow | Director Elections | Board | ABSTAIN | 4 |
| AMC Networks Inc. | 2025-06-05 | Election of the following nominees as Directors: Matthew C. Blank | Director Elections | Board | ABSTAIN | 4 |
| AMC Networks Inc. | 2025-06-05 | Vote on Proposal to Approve the Company's Amended and Restated 2016 Employee Stock Plan | Compensation | Board | AGAINST | 4 |
| AMC Networks Inc. | 2025-06-05 | Vote on Proposal to Approve the Company's Redomestication to the State of Nevada by Conversion | Extraordinary Transactions | Board | AGAINST | 4 |
| ARS Pharmaceuticals, Inc. | 2025-06-25 | To elect the four nominees for Class II director named in the proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Richard Lowenthal | Director Elections | Board | ABSTAIN | 4 |
| ASP Isotopes Inc. | 2024-11-20 | Approval of the Quantum Leap Energy LLC 2024 Equity Incentive Plan, as amended. | Compensation | Board | AGAINST | 4 |
| ASP Isotopes Inc. | 2024-11-20 | Election of directors to serve as Class II directors for a three-year term: Duncan Moore, Ph.D. | Director Elections | Board | ABSTAIN | 4 |
| ASP Isotopes Inc. | 2024-11-20 | Election of directors to serve as Class II directors for a three-year term: Michael Gorley, Ph.D. | Director Elections | Board | ABSTAIN | 4 |
| AST Spacemobile, Inc. | 2024-09-10 | To approve the AST SpaceMobile, Inc. 2024 Incentive Award Plan. | Compensation | Board | AGAINST | 4 |
| AST Spacemobile, Inc. | 2024-09-10 | To elect ten directors to the Company's Board of Directors for a term expiring at the Company's 2025 Annual Meeting of Stockholders: Abel Avellan | Director Elections | Board | ABSTAIN | 4 |
| AVITA Medical, Inc. | 2025-06-04 | To approve (a) the 2020 Omnibus Incentive Plan Amended and Restated (the "Plan"), the terms of which are summarized in this Proxy Statement; and (b) for purposes of ASX Listing Rule 7.2 Exception 13(b), which provides an exception to ASX Listing Rule 7.1, the issuance of the Company's equity securities under the Plan, in accordance with its terms and conditions, for a period of up to three years from the date of stockholder approval. | Compensation | Board | AGAINST | 4 |
| Achieve Life Sciences, Inc. | 2025-06-04 | To approve an amendment to our 2023 Non-Employee Director Equity Incentive Plan to increase the number of shares available for issuance thereunder. | Compensation | Board | AGAINST | 4 |
| Acrivon Therapeutics, Inc. | 2025-06-13 | Election of Class III Directors: Derek DiRocco, Ph.D. | Director Elections | Board | ABSTAIN | 4 |
| Acrivon Therapeutics, Inc. | 2025-06-13 | Election of Class III Directors: Santhosh Palani, Ph.D., C.F.A. | Director Elections | Board | ABSTAIN | 4 |
| Acumen Pharmaceuticals, Inc. | 2025-06-04 | To elect three Class I directors, to the Board of Directors, each to hold office until the 2028 Annual Meeting of Stockholders, and until his or her successor shall have been duly elected and qualified: Kimberlee C. Drapkin | Director Elections | Board | ABSTAIN | 4 |
| Acushnet Holdings Corp. | 2025-06-02 | Election of the following nominees for director: David Maher | Director Elections | Board | ABSTAIN | 4 |
| Acushnet Holdings Corp. | 2025-06-02 | Election of the following nominees for director: Ho Yeon (Aaron) Lee | Director Elections | Board | ABSTAIN | 4 |
| Acushnet Holdings Corp. | 2025-06-02 | Election of the following nominees for director: Keun Chang (Kevin) Yoon | Director Elections | Board | ABSTAIN | 4 |
| Acushnet Holdings Corp. | 2025-06-02 | Election of the following nominees for director: Yoon Soo (Gene) Yoon | Director Elections | Board | ABSTAIN | 4 |
| Adaptive Biotechnologies Corporation | 2025-06-10 | To elect one Class III director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2028 annual meeting of shareholders: Chad Robins | Director Elections | Board | ABSTAIN | 4 |
| Advanced Flower Capital Inc. | 2025-05-19 | Election of Director: Robert Levy | Director Elections | Board | AGAINST | 4 |
| Adverum Biotechnologies, Inc. | 2025-06-17 | Election of Class II Directors: James Scopa | Director Elections | Board | ABSTAIN | 4 |
| Adverum Biotechnologies, Inc. | 2025-06-17 | Election of Class II Directors: Laurent Fischer, M.D. | Director Elections | Board | ABSTAIN | 4 |
| Adverum Biotechnologies, Inc. | 2025-06-17 | Election of Class II Directors: Patrick Machado | Director Elections | Board | ABSTAIN | 4 |
| Adverum Biotechnologies, Inc. | 2025-06-17 | To approve the amendment and restatement of the Adverum Biotechnologies, Inc. 2024 Equity Incentive Award Plan. | Compensation | Board | AGAINST | 4 |
| Adverum Biotechnologies, Inc. | 2025-06-17 | To approve the amendment of certain outstanding stock options to reduce the exercise price per share to the closing price on the date of repricing. | Compensation | Board | AGAINST | 4 |
| AerSale Corporation | 2025-06-05 | To approve the Second Amendment to the AerSale Corporation 2020 Equity Incentive Plan; | Compensation | Board | AGAINST | 4 |
| Aerovate Therapeutics, Inc. | 2025-04-16 | Elect the three Class I directors, Mark Iwicki, Timothy P. Noyes, and Donald J. Santel, to Aerovate's board of directors and to hold office until Aerovate's 2028 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal; provided that if the Merger is consummated, the approval of Proposal No. 7 will only have an effect until the completion of the Merger because the composition of Aerovate's board of directors will be reconstituted upon completion of the Merger, in accordance with the Merger Agreement (the "Director Election Proposal" or "Proposal No. 7"): Mark Iwicki | Director Elections | Board | ABSTAIN | 4 |
| Aerovate Therapeutics, Inc. | 2025-04-16 | To approve the Jade Biosciences, Inc. 2025 Stock Incentive Plan (the "Stock Plan Proposal" or "Proposal No. 5"); | Compensation | Board | AGAINST | 4 |
| Agenus Inc. | 2025-06-17 | To approve a one-time exchange modification of options to purchase shares under our 2019 EIP, our Amended and Restated 2009 Equity Incentive Plan, and our 2015 Inducement Equity Plan. | Compensation | Board | AGAINST | 4 |
| Agenus Inc. | 2025-06-17 | To approve an amendment to our Amended and Restated 2019 Equity Incentive Plan ("2019 EIP") to increase the number of shares of common stock authorized for issuance thereunder from 5,050,000 shares to 12,050,000 shares. | Compensation | Board | AGAINST | 4 |
| Agenus Inc. | 2025-06-17 | To approve, in a non-binding advisory vote, the compensation of the Company's named executive officers. | Say-on-Pay | Board | AGAINST | 4 |
| Air Transport Services Group, Inc. | 2025-02-10 | To approve, by advisory (non-binding) vote, the compensation that may be paid or become payable to the Company's named executive officers in connection with the consummation of the merger (the "Advisory Compensation Proposal"); and | Say-on-Pay | Board | AGAINST | 4 |
| AirSculpt Technologies, Inc. | 2025-05-07 | Election of Directors: Dan Sollof | Director Elections | Board | AGAINST | 4 |
| AirSculpt Technologies, Inc. | 2025-05-07 | Election of Directors: Yogesh Jashnani | Director Elections | Board | AGAINST | 4 |
| Airship AI Holdings, Inc. | 2024-12-13 | Election of Directors: Peeyush Ranjan | Director Elections | Board | ABSTAIN | 4 |
← Previous Page 8 of 26 Next →
← Back to Guggenheim 2024-2025 overview
Built 2026-10-04 from SEC Form N-PX filings.